financetom
Business
financetom
/
Business
/
Newell Brands Q2 Earnings Likely Near Top End of Guidance; Full-Year Outlook Seen Unchanged, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Newell Brands Q2 Earnings Likely Near Top End of Guidance; Full-Year Outlook Seen Unchanged, UBS Says
Jul 19, 2024 12:09 PM

02:55 PM EDT, 07/19/2024 (MT Newswires) -- Newell Brands ( NWL ) is expected to report Q2 earnings at the upper end of the company's guidance and reiterate its full-year 2024 outlook when it releases its quarterly results on July 26, UBS said in a note emailed Friday.

The investment firm projects Q2 earnings of $0.20 per share, near the upper end of Newell's guidance range of $0.18 to $0.21, but below the Visible Alpha/FactSet consensus of $0.22, according to the note.

The consumer goods company is initially looking at 2024 normalized earnings of $0.52 to $0.62 per share and a net sales decline of 8% to 5%.

"Our conversations would suggest that most investors have confidence in the company's ability to deliver on their profit targets, but uncertainty on the top line remains and has led many to question whether there could be negative estimate revisions from here," UBS said.

UBS has a neutral rating on the stock and a $6.50 price target.

Price: 6.45, Change: -0.08, Percent Change: -1.23

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform
Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform
Jan 10, 2025
04:39 AM EST, 01/10/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said late Thursday it has struck a licensing agreement to use MediLink Therapeutics' Tmalin antibody-drug conjugate platform for the development of its ZL-6201 investigational drug. Financial terms were not disclosed. Zai Lab ( ZLAB ) said the partnership will expand its oncology pipeline with another drug targeting multiple...
Amylyx Pharmaceuticals Launches Stock Offering
Amylyx Pharmaceuticals Launches Stock Offering
Jan 10, 2025
04:31 AM EST, 01/10/2025 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said late Thursday it has commenced an underwritten public offering of common shares. Amylyx plans to give the underwriter a 30-day option to buy up to an additional 15% of the shares offered. The company said the proceeds will be used to support commercialization, pipeline programs, working capital...
Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth
Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth
Jan 10, 2025
04:39 AM EST, 01/10/2025 (MT Newswires) -- Innate Pharma ( IPHA ) said Friday it is prioritizing its antibody-based NK Cell Engager platform to target hematologic cancers, solid tumors, and autoimmune diseases. The company said it is currently testing its NK Cell Engager, IPH6501, in a phase 1/2 trial for non-Hodgkin's lymphoma. Additionally, Innate said it is advancing its Antibody-Drug...
India names Diageo, Sequoia Capital in case alleging suspicious payments
India names Diageo, Sequoia Capital in case alleging suspicious payments
Jan 10, 2025
* Diageo ( DEO ), Sequoia Capital face influence-peddling investigation * Diageo ( DEO ) made payment to lift ban on duty-free items -agency * Sequoia made payments for investment approval -agency By Arpan Chaturvedi NEW DELHI, Jan 10 (Reuters) - India's federal investigating agency has accused liquor giant Diageo ( DEO ) and Sequoia Capital of making suspicious payments...
Copyright 2023-2026 - www.financetom.com All Rights Reserved